Overall, it appears that CD226 and PD-1/PD-L1 are correlated with multiple cancer types, suggesting that CD226 activation may compliment anti-PD-L1/PD-1 immunotherapy by activating distinct T cell subsets with synergistic effects. This evidence concerns the gene PDCD1 and cancer.